Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$-11 Mln
ROE
-35.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
90,761,104
CFO
$-435.94 Mln
EBITDA
$-628.87 Mln
Net Profit
$-534.45 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Infinity Pharmaceuticals (INFI)
| -99.3 | -5.1 | -95.9 | -99.3 | -87.7 | -69.2 | -56.3 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Infinity Pharmaceuticals (INFI)
| -75.1 | 6.1 | 120.8 | -18.6 | -41.7 | 50.4 | -82.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Infinity Pharmaceuticals (INFI)
|
0.0 | 0.7 | 2.6 | -39.9 | -1,640.8 | -- | -- | 8.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage... immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Chairman & CEO
Ms. Adelene Q. Perkins
Chairman & CEO
Ms. Adelene Q. Perkins
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Infinity Pharmaceuticals Inc (INFI) is $0.00 (NASDAQ) as of 01-Dec-2023 09:30 EDT. Infinity Pharmaceuticals Inc (INFI) has given a return of -87.72% in the last 3 years.
Since, TTM earnings of Infinity Pharmaceuticals Inc (INFI) is negative, P/E ratio is not available.
The P/B ratio of Infinity Pharmaceuticals Inc (INFI) is 8.03 times as on 20-Dec-2023, a 104 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.15
|
-2.60
|
|
2021
|
-4.41
|
9.29
|
|
2020
|
-3.17
|
-5.91
|
|
2019
|
-1.16
|
7.09
|
|
2018
|
-5.97
|
1.28
|
The 52-week high and low of Infinity Pharmaceuticals Inc (INFI) are Rs -- and Rs -- as of 03-Apr-2026.
Infinity Pharmaceuticals Inc (INFI) has a market capitalisation of $ 1 Mln as on 20-Dec-2023. As per SEBI classification, it is a company.
Before investing in Infinity Pharmaceuticals Inc (INFI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.